PALI · Palisade Bio Inc. Common Stock
View on chartInsiders & Stakes
| John David Finley CEO CFO | ▼ Sell | Tax Withholding | 1,944,690 Shares held | 10/6/2026 | View profile |
| Mitchell Lawrence Jones See Remarks | ▼ Sell | Tax Withholding | 1,683,757 Shares held | 10/6/2026 | View profile |
| Donald Allen Williams Director | ▲ Buy | Open Market | 1,590,294 Shares held | 10/2/2026 | View profile |
| Binxian Wei Director | ▲ Buy | Option Exercise | 613,355 Shares held | 6/10/2026 | View profile |
| Emil Chuang Director | ▲ Buy | Option Exercise | 612,500 Shares held | 6/10/2026 | View profile |
| Robert Baltera Jr. Director | ▲ Buy | Open Market | 461,904 Shares held | 7/9/2026 | View profile |
| Jordan Michael Zwick Director | ▲ Buy | Grant | 336,904 Shares held | 6/10/2026 | View profile |
| Hallam Thomas Chief Executive Officer | ▲ Buy | Open Market | 57,592 Shares held | 8/16/2022 | View profile |
| Dawson Michael John Chief Medical Officer | ▲ Buy | Open Market | 15,000 Shares held | 3/29/2022 | View profile |
| Csimma Cristina Director | ▲ Buy | Option Exercise | 12,862 Shares held | 2/8/2024 | View profile |
| Diaz Stephanie Director | ▲ Buy | Option Exercise | 12,800 Shares held | 2/8/2024 | View profile |
| James R. Neal Director | ▲ Buy | Option Exercise | 10,920 Shares held | 2/9/2024 | View profile |
| Trenschel Robert J. Director | ▲ Buy | Option Exercise | 10,920 Shares held | 2/8/2024 | View profile |
| McRae Robert Curtis Chief Operating Officer | ▼ Sell | Tax Withholding | 625 Shares held | 4/3/2023 | View profile |
Transaction History
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 2,620,850 | — | 10/6/2026 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 1,031,102 | $1.5M | 10/6/2026 |
| John David Finley | ▲ Buy | Option Exercise | 3,227,384 | — | 10/6/2026 |
| John David Finley | ▼ Sell | Tax Withholding | 1,411,982 | $2.1M | 10/6/2026 |
| Donald Allen Williams | ▲ Buy | Open Market | 10,000 | $15K | 10/2/2026 |
| Donald Allen Williams | ▲ Buy | Open Market | 10,000 | $14K | 10/1/2026 |
| John David Finley | ▼ Sell | Gift | 88,400 | $0 | 8/19/2026 |
| John David Finley | ▼ Sell | Gift | 88,400 | $0 | 8/19/2026 |
| Robert Baltera Jr. | ▲ Buy | Open Market | 25,000 | $49K | 7/9/2026 |
| Robert Baltera Jr. | ▲ Buy | Open Market | 20,000 | $40K | 7/8/2026 |
| Robert Baltera Jr. | ▲ Buy | Open Market | 30,000 | $61K | 7/7/2026 |
| Mitchell Lawrence Jones | ▼ Sell | Open Market | 51,880 | $107K | 7/7/2026 |
| John David Finley | ▼ Sell | Open Market | 146,798 | $303K | 7/7/2026 |
| John David Finley | ▲ Buy | Option Exercise | 133 | $93 | 7/7/2026 |
| Robert Baltera Jr. | ▲ Buy | Open Market | 20,000 | $41K | 7/6/2026 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 131,167 | — | 7/6/2026 |
| John David Finley | ▲ Buy | Option Exercise | 335,167 | — | 7/6/2026 |
| Robert Baltera Jr. | ▲ Buy | Open Market | 10,000 | $20K | 7/2/2026 |
| Robert Baltera Jr. | ▲ Buy | Open Market | 20,000 | $40K | 7/1/2026 |
| Binxian Wei | ▲ Buy | Grant | 592,300 | — | 6/10/2026 |
| Binxian Wei | ▲ Buy | Option Exercise | 20,200 | — | 6/10/2026 |
| Donald Allen Williams | ▲ Buy | Grant | 1,498,900 | — | 6/10/2026 |
| Donald Allen Williams | ▲ Buy | Option Exercise | 60,666 | — | 6/10/2026 |
| Emil Chuang | ▲ Buy | Grant | 592,300 | — | 6/10/2026 |
| Emil Chuang | ▲ Buy | Option Exercise | 20,200 | — | 6/10/2026 |
| Jordan Michael Zwick | ▲ Buy | Grant | 336,904 | — | 6/10/2026 |
| Robert Baltera Jr. | ▲ Buy | Grant | 336,904 | — | 6/10/2026 |
| Mitchell Lawrence Jones | ▼ Sell | Open Market | 1,989 | $3K | 2/12/2026 |
| John David Finley | ▼ Sell | Open Market | 3,896 | $7K | 2/12/2026 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 8,000 | — | 2/11/2026 |
| John David Finley | ▲ Buy | Option Exercise | 13,333 | — | 2/11/2026 |
| Donald Allen Williams | ▲ Buy | Open Market | 5,000 | $8K | 1/16/2026 |
| Donald Allen Williams | ▲ Buy | Open Market | 5,000 | $9K | 1/9/2026 |
| Binxian Wei | ▲ Buy | Option Exercise | 388 | $0 | 11/21/2024 |
| Donald Allen Williams | ▲ Buy | Option Exercise | 388 | $0 | 11/21/2024 |
| Binxian Wei | ▲ Buy | Option Exercise | 465 | $0 | 6/11/2024 |
| Donald Allen Williams | ▲ Buy | Option Exercise | 340 | $0 | 6/11/2024 |
| John David Finley | ▼ Sell | Tax Withholding | 467 | $2K | 5/28/2024 |
| John David Finley | ▲ Buy | Option Exercise | 3,335 | $0 | 5/28/2024 |
| John David Finley | ▼ Sell | Tax Withholding | 959 | $5K | 5/28/2024 |
| John David Finley | ▲ Buy | Option Exercise | 2,111 | $0 | 5/28/2024 |
| John David Finley | ▼ Sell | Tax Withholding | 607 | $3K | 5/28/2024 |
| Donald Allen Williams | ▲ Buy | Open Market | 1,000 | $5K | 5/28/2024 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 2,735 | $0 | 5/28/2024 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 810 | $4K | 5/28/2024 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 1,555 | $0 | 5/28/2024 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 461 | $2K | 5/28/2024 |
| John David Finley | ▲ Buy | Option Exercise | 1,622 | $0 | 5/28/2024 |
| John David Finley | ▲ Buy | Open Market | 1,000 | $5K | 5/24/2024 |
| John David Finley | ▲ Buy | Grant | 666 | $3K | 5/20/2024 |
| John David Finley | ▲ Buy | Option Exercise | 232 | $0 | 5/6/2024 |
| John David Finley | ▼ Sell | Tax Withholding | 67 | $567 | 5/6/2024 |
| John David Finley | ▲ Buy | Option Exercise | 211 | $0 | 5/6/2024 |
| John David Finley | ▼ Sell | Tax Withholding | 61 | $516 | 5/6/2024 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 304 | $0 | 5/6/2024 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 90 | $761 | 5/6/2024 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 156 | $0 | 5/6/2024 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 47 | $398 | 5/6/2024 |
| John David Finley | ▲ Buy | Option Exercise | 5,558 | $0 | 3/11/2024 |
| James R. Neal | ▲ Buy | Option Exercise | 5,100 | $0 | 2/9/2024 |
| James R. Neal | ▲ Buy | Option Exercise | 5,820 | $0 | 2/9/2024 |
| Csimma Cristina | ▲ Buy | Option Exercise | 6,980 | $0 | 2/8/2024 |
| Trenschel Robert J. | ▲ Buy | Option Exercise | 5,100 | $0 | 2/8/2024 |
| Diaz Stephanie | ▲ Buy | Option Exercise | 6,980 | $0 | 2/8/2024 |
| Diaz Stephanie | ▲ Buy | Option Exercise | 5,820 | $0 | 2/8/2024 |
| Trenschel Robert J. | ▲ Buy | Option Exercise | 5,820 | $0 | 2/8/2024 |
| Csimma Cristina | ▲ Buy | Option Exercise | 5,820 | $0 | 2/8/2024 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 4,558 | $0 | 2/6/2024 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 2,333 | $0 | 2/6/2024 |
| John David Finley | ▲ Buy | Option Exercise | 3,475 | $0 | 2/6/2024 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 2,153 | $939 | 2/6/2024 |
| John David Finley | ▲ Buy | Option Exercise | 3,167 | $0 | 2/6/2024 |
| John David Finley | ▲ Buy | Open Market | 10,000 | $5K | 2/6/2024 |
| John David Finley | ▲ Buy | Open Market | 10,000 | $6K | 1/31/2024 |
| Donald Allen Williams | ▲ Buy | Open Market | 10,000 | $6K | 1/31/2024 |
| John David Finley | ▲ Buy | Option Exercise | 1,309 | $0 | 1/3/2024 |
| John David Finley | ▲ Buy | Option Exercise | 5,559 | $0 | 12/11/2023 |
| John David Finley | ▲ Buy | Grant | 10,000 | $5K | 11/20/2023 |
| Mitchell Lawrence Jones | ▼ Sell | Tax Withholding | 1,630 | $878 | 11/7/2023 |
| Mitchell Lawrence Jones | ▲ Buy | Option Exercise | 4,556 | $0 | 11/6/2023 |
| John David Finley | ▲ Buy | Option Exercise | 3,475 | $0 | 11/6/2023 |
| John David Finley | ▼ Sell | Tax Withholding | 397 | $218 | 10/4/2023 |
| John David Finley | ▲ Buy | Option Exercise | 1,309 | $0 | 10/3/2023 |
| Donald Allen Williams | ▲ Buy | Open Market | 20,000 | $11K | 9/27/2023 |
| John David Finley | ▲ Buy | Open Market | 15,000 | $8K | 9/27/2023 |
| Trenschel Robert J. | ▼ Sell | Open Market | 300 | $192 | 9/14/2023 |
| John David Finley | ▲ Buy | Open Market | 15,000 | $10K | 9/13/2023 |
| John David Finley | ▼ Sell | Tax Withholding | 1,792 | $1K | 9/12/2023 |
| John David Finley | ▲ Buy | Option Exercise | 5,558 | $0 | 9/11/2023 |
| John David Finley | ▼ Sell | Tax Withholding | 1,040 | $728 | 8/11/2023 |
| John David Finley | ▲ Buy | Option Exercise | 3,475 | $0 | 8/6/2023 |
| John David Finley | ▼ Sell | Tax Withholding | 389 | $686 | 7/6/2023 |
| John David Finley | ▲ Buy | Option Exercise | 1,309 | $0 | 7/3/2023 |
| John David Finley | ▼ Sell | Tax Withholding | 1,050 | $2K | 6/13/2023 |
| John David Finley | ▲ Buy | Option Exercise | 3,475 | $0 | 6/12/2023 |
| McRae Robert Curtis | ▲ Buy | Option Exercise | 655 | $0 | 4/3/2023 |
| McRae Robert Curtis | ▼ Sell | Tax Withholding | 270 | $540 | 4/3/2023 |
| John David Finley | ▲ Buy | Option Exercise | 1,309 | $0 | 4/3/2023 |
| John David Finley | ▼ Sell | Tax Withholding | 435 | $874 | 4/3/2023 |
| John David Finley | ▲ Buy | Open Market | 19,481 | $3K | 9/1/2022 |
| John David Finley | ▲ Buy | Open Market | 7,350 | $1K | 8/23/2022 |
| Hallam Thomas | ▲ Buy | Open Market | 40,000 | $10K | 8/16/2022 |
| John David Finley | ▲ Buy | Open Market | 100,000 | $25K | 8/16/2022 |
| John David Finley | ▼ Sell | Other | 12,545 | $0 | 4/29/2022 |
| Dawson Michael John | ▲ Buy | Open Market | 15,000 | $17K | 3/29/2022 |
| Hallam Thomas | ▲ Buy | Open Market | 10,000 | $12K | 3/28/2022 |
| John David Finley | ▲ Buy | Open Market | 7,500 | $8K | 3/24/2022 |
| Hallam Thomas | ▲ Buy | Open Market | 6,000 | $15K | 9/21/2021 |
| John David Finley | ▲ Buy | Open Market | 2,000 | $5K | 9/21/2021 |
| Trenschel Robert J. | ▲ Buy | Open Market | 2,142 | $6K | 9/10/2021 |
| Trenschel Robert J. | ▲ Buy | Open Market | 3,400 | $10K | 9/9/2021 |
| Trenschel Robert J. | ▲ Buy | Open Market | 5,000 | $14K | 9/8/2021 |
| Trenschel Robert J. | ▲ Buy | Open Market | 2,707 | $8K | 9/7/2021 |
| Trenschel Robert J. | ▲ Buy | Open Market | 1,750 | $5K | 8/31/2021 |
| John David Finley | ▲ Buy | Open Market | 1,600 | $4K | 8/27/2021 |
| John David Finley | ▲ Buy | Open Market | 8,400 | $22K | 8/27/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108
Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108. Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.